Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
aaiPharma, AbbVie, academic, acid, Adcirca, Allergan, amino, analyze, arterial, automatically, Barovic, biggest, Biogen, biotech, broaden, calcitonin, carryforward, Celgene, CER, CGRP, cisplatin, clarification, closure, commensurate, concomitantly, consumption, County, Crohn, dampen, deal, disallowance, disinterested, displaced, DNA, docetaxel, ehf, elevated, empowered, encourage, energy, enrichment, equitable, Euronext, expansion, frequent, Gilead, Glenmark, hacking, HTA, hypertension, Idec, illustrated, immaterial, indemnification, indirect, ineffectual, injector, Kim, Korea, lodged, malware, Marion, MCO, media, Medtronic, NeoSan, nonclinical, notional, NYSE, opposition, outbreak, outlined, paclitaxel, PCORI, peglispro, pemetrexed, PRELUDE, prospective, pulmonary, purportedly, RAINBOW, Ratify, receipt, recombinant, refinancing, relapse, repatriated, REVEL, rolling, ROSE, salt, Sanofi, secret, sector, sequence, setoff, sharply, spinoff, SQUIRE, standalone, stemming, stored, Tai, talent, tanezumab, terrorism, thereof, thyroid, UK, uninterrupted, unjust, unspecified, voluntary, war, waste, weaker, wrongful
Removed:
AA, accessible, Acrux, aid, Alnara, amyloid, antitrust, Apralan, Armitage, array, ASU, Avid, Axid, bacterial, began, borrowed, brain, canine, categorized, cholesterol, collective, commercializing, compulsory, conjunction, cooperating, creditable, decertification, decertified, decertify, decided, defending, diet, discrete, disposing, divested, downturn, duloxetine, dyslipidemia, economy, Education, educational, enactment, enrollment, enteric, enzyme, Evonik, excise, excluding, exocrine, expiry, explore, FASB, florbetapir, goal, heightened, hoover, hyperlipidemia, ImClone, imposition, injunction, insufficiency, investigative, Lafayette, led, Livalo, London, matter, metabolic, modification, Moody, nonmonetary, norepinepherine, Northern, olanzapine, opposed, ordered, outlook, overtime, pathology, permanently, plaque, pose, positioning, Practice, preliminarily, preliminary, prepaid, prevented, pro, profitability, radiopharmaceutical, reclassification, Reconcile, reconsideration, recovered, repayment, represented, rest, restitution, reuptake, Robert, ruled, scan, separation, Sligo, software, sought, stream, streamline, strictly, subpoena, subsidy, Tippecanoe, tumor, update, upholding, utero, utilizing, violation, violative, voluntarily, waiting, weighted, West, Western, wide, worked
Filing tables
Filing exhibits
- 10-K Annual report
- 3.1 Amended Articles of Incorporation
- 10.5 the Lilly Deferred Compensation Plan
- 10.7 the Eli Lilly and Company Bonus Plan
- 12 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 21 List of Subsidiaries& Affiliates
- 23 Consent of Independent Registered Public Accounting Firm
- 31.1 Rule 13A-14(A) Certification of John C. Lechleiter, PH.D., Chairman of the Board
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, Global
- 32 SECTION1350 Certification
- Download Excel data file
- View Excel data file
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 32 Section 1350 Certification
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Eli Lilly and Company, an Indiana corporation (the “Company”), does hereby certify that, to the best of his knowledge:
The Annual Report on Form 10-K for the year ended December 31, 2013 (the “Form 10-K”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: | February 19, 2014 | /s/ John C. Lechleiter | |
| John C. Lechleiter, Ph.D. | |||
Chairman of the Board, President, and Chief Executive Officer | |||
| Date: | February 19, 2014 | /s/ Derica W. Rice | |
| Derica W. Rice | |||
Executive Vice President, Global Services and Chief Financial Officer | |||